Clinical Trial

Colchicine Use for Primary Prevention of Coronary Artery Disease

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Colchicine has been widely used as an anti-gout medicine in the past decades. Some recent clinical trials have proved that low-dose colchicine can be used as a secondary prevention drug for coronary artery disease because of its anti-inflammatory mechanism. However, the effect on primary prevention has not been observed sufficiently. The objective of this study is to determine whether colchicine reduces the incidence of CAD in patients and its safety for long-term use.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-12-14; most recent amendment 2022-03-06.
Trial Details
NCT Number NCT05175274
Lead Sponsor Qingdao Central Hospital
Collaborators: Qingdao Municipal Hospital
Conditions Coronary Artery Disease
Enrollment 6,792 participants
Start Date 2022-12-06
Primary Completion 2027-03-01 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2022-03-21